Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about Sphingomyelin: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
Knowledge base pages for this entity
| Target | Relation | Type | Str |
|---|---|---|---|
| APP | treats | gene | 0.65 |
| CYP46A1 | activates | gene | 0.65 |
| CYP46A1 | regulates | gene | 0.65 |
| AMYLOID-BETA | interacts_with | protein | 0.65 |
| ALZHEIMER'S DISEASE | treats | disease | 0.65 |
| OXIDATIVE STRESS | inhibits | phenotype | 0.65 |
| HIPPOCAMPUS | inhibits | brain_region | 0.65 |
| HIPPOCAMPUS | regulates | brain_region | 0.65 |
| HIPPOCAMPUS | expressed_in | brain_region | 0.55 |
| CERAMIDE | participates_in | phenotype | 0.55 |
| HIPPOCAMPUS | depleted_in | brain_region | 0.55 |
| HIPPOCAMPUS | associated_with | brain_region | 0.45 |
| CEREBELLUM | associated_with | brain_region | 0.45 |
| FINGOLIMOD | associated_with | drug | 0.45 |
| Source | Relation | Type | Str |
|---|---|---|---|
| SMS1 | catalyzes | enzyme | 0.95 |
| SGMS1 | catalyzes | gene | 0.95 |
| Alcohol Exposure | downregulates | process | 0.90 |
Hypotheses where this entity is a therapeutic target
| Hypothesis | Score | Disease | Analysis |
|---|---|---|---|
| Selective Acid Sphingomyelinase Modulation Therapy | 0.648 | neurodegeneration | Lipid raft composition changes in synapt |
| Selective Neutral Sphingomyelinase-2 Inhibition Therapy | 0.591 | neurodegeneration | Lipid raft composition changes in synapt |
| Neutral Sphingomyelinase-2 Inhibition for Synaptic Protectio | 0.546 | neurodegeneration | Lipid raft composition changes in synapt |
| SGMS1-Driven Sphingomyelin Accumulation Impairs BACE1 Lysoso | 0.542 | neurodegeneration | What molecular mechanisms link elevated |
| Sphingomyelin Synthase Activators for Raft Remodeling | 0.468 | neurodegeneration | Lipid raft composition changes in synapt |
Scientific analyses that reference this entity
neurodegeneration | 2026-04-15 | 1 hypotheses Top: 0.542
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| Coenzyme Q10 Supplementation Modulates Hepatic Lipidomic Alterations and Attenua [PMID:41754105] | Go Y, Joung H, Han SY, Chung J | Nutrients | 2026 | 0 |
| SMPD1 as a Potential Prognostic Biomarker in Glioma Is Associated With an Immuno [PMID:41795144] | Xu Y, Liu X, Xu B, Li Q, Zhang L, Li C, | CNS neuroscience & therapeutic | 2026 | 0 |
| Endogenous Ceramide 24:1 Constrains Th17-Driven Neutrophilic Inflammation by Ant [PMID:41824764] | Liu H, Aili A, Kuang Z, Cao L, Li Z, Sha | Advanced science (Weinheim, Ba | 2026 | 0 |
| Suspected Niemann-Pick disease type B with sea-blue histiocytosis after splenect [PMID:41791926] | Liu W, Qin L, Wang G | Journal of clinical lipidology | 2026 | 0 |
| Olipudase alfa treatment for pediatric acid sphingomyelinase deficiency in Egypt [PMID:41716780] | Arafa NA, Mahfouz A, Anwar S, Marzouk I | Molecular genetics and metabol | 2026 | 0 |
| Ceramide metabolism in oxidative and glycolytic muscle: Significance for lipid-i [PMID:41707846] | Eurén T, Flockhart M, Strmeň T, Zhou X, | Molecular metabolism | 2026 | 0 |
| Acid sphingomyelinase activity suggests a new antipsychotic pharmaco-treatment s [PMID:39825014] | Chestnykh D, Mühle C, Schumacher F, Kali | Molecular psychiatry | 2025 | 0 |
| Reduction of sphingomyelinase activity associated with progranulin deficiency an [PMID:40633679] | Boyle NR, Fox SN, Tadepalli AS, Seyfried | Neurobiology of disease | 2025 | 0 |
| Effect of Lactiplantibacillus mudanjiangensis strain isolated from post-fermente [PMID:41270786] | Horie M, Tabata Y, Aiso C, Gotoh Y | Beneficial microbes | 2025 | 0 |
| Bionanoconjugates in Neurodegeneration: Peptide-Nanoparticle Alliances for Next- [PMID:41199078] | ["Ranjitha V", "Kumar A", "Kaalappa P"] | Pharmaceutical research | 2025 | 0 |
| Identification of Anticancer Target Combinations to Treat Pancreatic Cancer and [PMID:40807373] | ["Wang F", "Wu C", "Huang K"] | Molecules (Basel, Switzerland) | 2025 | 0 |
| Exosomes as nanocarriers for brain-targeted delivery of therapeutic nucleic acid [PMID:40533746] | ["Sanadgol N", "Abedi M", "Hashemzaei M" | Journal of nanobiotechnology | 2025 | 0 |
| Acid sphingomyelinase as a pathological and therapeutic target in neurological d [PMID:38337058] | Choi BJ, Park MH, Jin HK, Bae JS | Experimental & molecular medic | 2024 | 0 |
| Optimal Control with RdCVFL for Degenerating Photoreceptors. [PMID:38345678] | ["Wifvat K", "Camacho E", "Kawski M", "L | Bulletin of mathematical biolo | 2024 | 0 |
| The Genetic Basis, Lung Involvement, and Therapeutic Options in Niemann-Pick Dis [PMID:38397448] | Tirelli C, Rondinone O, Italia M, Mira S | Biomolecules | 2024 | 0 |
| Consensus clinical management guidelines for acid sphingomyelinase deficiency (N [PMID:37069638] | Geberhiwot T, Wasserstein M, Wanninayake | Orphanet journal of rare disea | 2023 | 0 |
| Functional screening of lysosomal storage disorder genes identifies modifiers of [PMID:37200393] | Yu M, Ye H, De-Paula RB, Mangleburg CG, | PLoS genetics | 2023 | 0 |
| Case report: The spectrum of SMPD1 pathogenic variants in Hungary. [PMID:37347058] | ["Molnar M", "Szlepak T", "Cs\u00fcrke I | Frontiers in genetics | 2023 | 0 |
| The Niemann-Pick type diseases - A synopsis of inborn errors in sphingolipid and [PMID:37003582] | Pfrieger FW | Progress in lipid research | 2023 | 0 |
| Expression of Ceramide-Metabolizing Enzymes in the Heart Adipose Tissue of Cardi [PMID:37298446] | Gruzdeva O, Dyleva Y, Belik E, Uchasova | International journal of molec | 2023 | 0 |